Drug delivery and therapeutic impact of extended-release acetylsalicylic acid
| Autor: | Kevin P. Bliden, Jeff Patrick, Andrew T Pennell, Udaya S. Tantry, Paul A. Gurbel |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug Resistance
030204 cardiovascular system & hematology Pharmacology Delayed-Action Preparations 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Diabetes mellitus medicine Secondary Prevention Humans 030212 general & internal medicine Dosing Aspirin Dose-Response Relationship Drug business.industry medicine.disease digestive system diseases surgical procedures operative Cardiovascular Diseases Drug delivery Molecular Medicine Platelet aggregation inhibitor Extended release Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Future cardiology. 12(1) |
| ISSN: | 1744-8298 |
| Popis: | Current treatment guidelines recommend once-daily, low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention of cardiovascular events. However, the anti-thrombotic benefits of traditional ASA formulations may not extend over a 24-h period, especially in patients at high risk for a recurrent cardiovascular event. A next-generation, extended-release ASA formulation (ER-ASA) has been developed to provide 24-h anti-thrombotic coverage with once-daily dosing. The pharmacokinetics of ER-ASA indicates slower absorption and prolonged ASA release versus immediate-release ASA, with a favorable safety profile. ER-ASA minimizes systemic ASA absorption and provides sustained antiplatelet effects over a 24-h period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|